BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5, Comirnaty JN.1 and Comirnaty KP.2 may be administered concomitantly with a pneumococcal conjugated vaccine (PCV). an unadjuvanted ...

EMA committee recommends marketing approval of Pfizer & BioNTech’s LP.8.1-adapted Covid-19 vaccine: New York Saturday, July 26, 2025, 10:00 Hrs [IST] Pfizer Inc. and BioNTech SE ...

Turkish scientists say that Pfizer's COVID-19 vaccine can increase the risk of eye damage, causing vision loss. A new study ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

What's next for Pfizer and BioNTech. Pfizer reported second-quarter sales of Comirnaty, the partners' approved COVID-19 vaccine, that plummeted 87% year over year to just $195 million.

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202 ...